Efficacy and Safety of Bruton Tyrosine Kinase Inhibitor Monotherapy Compared with Combination Therapy for Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: A Systematic Review and Meta-Analysis

SIMPLE SUMMARY: The approval of combination treatments such as chemoimmunotherapy was a breakthrough in managing chronic lymphocytic leukemia and small lymphocytic lymphoma (CLL/SLL) patients. However, benefits remain suboptimal. A Bruton tyrosine kinase inhibitor (BTKi) is an effective treatment fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Nguyen, Thi Thuy, Nhu, Nguyen Thanh, Tran, Van Khoi, Nguyen, Tran Thuc Huan, Lin, Chiou-Feng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093473/
https://www.ncbi.nlm.nih.gov/pubmed/37046657
http://dx.doi.org/10.3390/cancers15071996

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10093473/
https://www.ncbi.nlm.nih.gov/pubmed/37046657
http://dx.doi.org/10.3390/cancers15071996

Ejemplares similares